Medical

Pulmatrix said that the first subjects have been dosed in a Phase 1 trial of the company's PUR3100 dry powder dihydroergotamine (DHE), which is based on Pulmatrix's iSPERSE particle engineering platform. The company announced in March 2021 that it intended to develop the PUR3100 DPI for the treatment of migraines. The Phase 1 trial is expected to enroll 24 healthy … [Read more...] about Pulmatrix initiates Phase 1 trial of PUR3100 inhaled dry powder DHE

US-based startup RS BioTherapeutics has announced that a proof of concept study demonstrated that its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) reduced but did not eliminate cytokines when dosed intranasally at 1 mg/kg in a mouse model of pulmonary inflammation. The study was conducted by researchers at Marshall University. RS BioTherapeutics licensed the … [Read more...] about RS BioTherapeutics reports positive preclinical results for its inhaled CBDa

Danish startup Cessatech, a spin out from Rigshospitalet, announced that it has gotten the go-ahead for a pivotal trial of its CT001 analgesic nasal spray. Cessatech is developing CT001, a fixed dose combination of sufentanil and ketamine, for use in pediatric patients and has already completed dosing in a Phase 2 PK study of the nasal spray in children aged 1-17. … [Read more...] about Cessatech announces plans for pivotal trial of CT001 intranasal analgesic

Orexo announced the initiation of a Phase 1 trial of its OX640 intranasal dry powder adrenaline, which the company is developing for emergency treatment of anaphylaxis. The OX640-001 study will compare several formulations of OX640 to intramuscular adrenaline in healthy volunteers. OX640 is based on Orexo's amorphOX particle engineering technology, which is also … [Read more...] about Orexo initiates Phase 1 trial of OX640 intranasal dry powder adrenaline

Receptor Life Sciences said that a Phase 1b/2a trial of its RLS103 cannabidiol DPI in social anxiety disorder patients with acute anxiety has gotten underway. The trial is expected to enroll approximately 30 patients who will get either 3 mg of RLS103, 6 mg of RLS103, or an inhaled dry powder placebo prior to a public speaking challenge. The RLS103 formulation … [Read more...] about Receptor initiates Phase 1b/2a trial of RLS103 dry powder CBD in patients with SAD

FluGen said that the first subject has been dosed in a Phase 1b study of its M2SR intranasal live single replication flu vaccine and an intramuscular high dose inactivated vaccine (IIV) in adults aged 65 to 85 years. The study, which is funded by the US Department of Defense, will evaluate each of the vaccines separately, as well as the intranasal and IIV vaccines … [Read more...] about Phase 1b study of FluGen’s intranasal flu vaccine in older adults gets underway

Oragenics has published data from studies of its NT-CoV-2-1 proteosome adjuvanted intranasal vaccine candidate against SARS-CoV-2 in mice and hamsters that support further development of the vaccine, the company said. The data were published June 13, 2022 in an article in Nature's Scientific Reports titled "Intranasal Immunization with a Proteosome-Adjuvanted … [Read more...] about Oragenics says preclinical data support further development of its intranasal COVID-19 vaccine

Optinose has announced that the Phase 3 ReOpen2 trial of Xhance fluticasone propionate nasal spray (OPN-375) in patients with chronic sinusitis without nasal polyps demonstrated significant improvement compared to placebo in both patient reported symptoms at week 4 and inflammation measured by CT scan at week 24. The FDA approved Xhance in 2017 for the treatment of … [Read more...] about Phase 3 ReOpen2 trial of Optinose’s Xhance intranasal fluticasone meets primary endpoints

Tiziana Life Sciences has announced that a second multiple sclerosis patient who received the company's intranasal foralumab for three months as part of an expanded access program at Brigham and Women’s Hospital (BWH) has showed significant improvement.  According to Tiziana, PET imaging demonstrated inhibition of microglial activation, and the patient also showed … [Read more...] about Tiziana reports positive results for intranasal foralumab in second MS patient